Stivarga (regorafenib; Bayer/Amgen) Drug Overview 2019

Drug Pipelines
30 Pages
September 2019
Region: Global
Citeline
ID: 4462150

Drug Overview
Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients.

It is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and fibroblast growth factor receptor), stromal, and oncogenic (KIT, RET, and BRAF) kinases. It is currently also approved for the third-line treatment of metastatic colorectal cancer and the second-line treatment of gastrointestinal stromal tumor.

OVERVIEW

Drug Overview
Product Profiles
Stivarga : Hepatocellular carcinoma (HCC)
Stivarga : Colorectal cancer (CRC)

LIST OF FIGURES

Figure 1: The author's drug assessment summary of Stivarga for HCC
Figure 2: The author's drug assessment summary of Stivarga for HCC
Figure 3: Stivarga sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Stivarga for colorectal cancer – SWOT analysis
Figure 5: The author's drug assessment summary of Stivarga for colorectal cancer
Figure 6: The author's drug assessment summary of Stivarga for colorectal cancer
Figure 7: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Stivarga drug profile
Table 2: Approval history of Stivarga for HCC in the US, Japan, and five major EU markets
Table 3: Trials of Stivarga for HCC
Table 4: Stivarga for HCC – SWOT analysis
Table 5: Stivarga drug profile
Table 6: Stivarga pivotal trial data in colorectal cancer
Table 7: Stivarga ongoing trials in colorectal cancer
Table 8: Stivarga sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 9: Patients treated with Stivarga across the US, Japan, and five major EU markets, by country, 2016–25

Table of Contents

Related Topics

Related Products

Regorafenib Drug Insight and Market Forecast - 2032

Metastatic Colorectal Cancer Drugs Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2028F

United States Liver Cancer Therapeutics Market, Competition, Forecast and Opportunities, 2018-2028

Hepatocellular Carcinoma - Pipeline Insight, 2024

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029